SCHEMBL422792

SCHEMBL422792

CC(C)(c1cccc(C(F)(F)F)c1)N1CCC(=O)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.43
CYP2B6 P20813 1/20 0.41
LMNA P02545 2/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
TACR1 P25103 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
HTR1D P28221 1/20 0.39
HTR2C P28335 1/20 0.39
HTR3A P46098 1/20 0.39
HTR3D Q70Z44 1/20 0.39
HTR3C Q8WXA8 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3707837 0.80 CYP2B6 (0.63) CYP2B6LMNAPOLBALDH1A1MAPT
SCHEMBL3660752 0.74 ALDH1A1 (0.64) ALOX5LMNAPOLBALDH1A1HTR3E
SCHEMBL423832 0.74 LMNA (0.39) CYP2B6LMNAPOLBHPGDTACR1
SCHEMBL3708789 0.73 CYP2B6 (0.42) CYP2B6TACR1ALDH1A1MAPTMEN1
SCHEMBL4698249 0.71 KDM4E (0.70) LMNAPOLBTACR1ALDH1A1SIGMAR1
SCHEMBL24407625 0.70 CYP2B6 (0.42) CYP2B6
SCHEMBL31583791 0.70 CYP2B6 (0.42) CYP2B6POLBHPGDMEN1KMT2A
SCHEMBL2295165 0.70 LMNA (0.74) LMNAPOLBHPGDALDH1A1GAA
SCHEMBL1677156 0.70 HTT (0.65) LMNAHPGDALDH1A1MAPTKDM4E
SCHEMBL27989957 0.69 ALDH1A1 (0.58) ALOX5LMNAPOLBALDH1A1HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895551-B2 Acrylamide compounds and the use thereof SHIONOGI & CO., LTD. (JP) 2014-11-25 US disclosed
EP-2414332-B1 ACRYLAMIDE COMPOUNDS AND THE USE THEREOF SHIONOGI & CO (JP) 2013-10-23 EP disclosed
EP-2414332-A1 ACRYLAMIDE COMPOUNDS AND THE USE THEREOF Shionogi & Co., Ltd. (JP) 2012-02-08 EP disclosed
US-20120022069-A1 ACRYLAMIDE COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2012-01-26 US disclosed
WO-2010114181-A1 ACRYLAMIDE COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2010-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022069-A1 ACRYLAMIDE COMPOUNDS AND THE USE THEREOF TRPA1, TRPV1, CACNA1B ALOX5 402/4885CYP2B6 964/4885LMNA 2615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.